Treace Medical Concepts, Inc. Stock-Based Compensation
Treace Medical Concepts, Inc. (TMCI) reported Stock-Based Compensation of $14.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-07
- Treace Medical Concepts, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $6.46M, a 32.52% decline year-over-year.
- Treace Medical Concepts, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $8.03M, a 7.58% decline year-over-year.
- Treace Medical Concepts, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $7.55M, a 11.69% decline year-over-year.
- Treace Medical Concepts, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $8.00M, a 1.24% increase year-over-year.
- Treace Medical Concepts, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $33.82M, a 10.52% increase from fiscal 2024.
- Treace Medical Concepts, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $30.60M, a 76.37% increase from fiscal 2023.
- Treace Medical Concepts, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $17.35M, a 113.93% increase from fiscal 2022.
- Treace Medical Concepts, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $8.11M, a 137.93% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $14.50M 10-Q · filed 2026-08-07 | $22.05M derived: sum of 3 quarters · filed 2026-08-07 | $30.05M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $8.03M 10-Q · filed 2026-05-08 | $15.59M derived: sum of 2 quarters · filed 2026-05-08 | $23.59M derived: sum of 3 quarters · filed 2026-05-08 | $33.16M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $7.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $15.55M derived: sum of 2 quarters · filed 2026-02-27 | $25.13M derived: sum of 3 quarters · filed 2026-08-07 | $33.82M 10-K · filed 2026-02-27 |
| 2025-09-30 | $8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $17.57M derived: sum of 2 quarters · filed 2026-08-07 | $26.27M 10-Q · filed 2025-11-06 | $34.82M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $9.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $18.27M 10-Q · filed 2026-08-07 | $26.82M derived: sum of 3 quarters · filed 2026-08-07 | $34.73M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $8.69M 10-Q · filed 2026-05-08 | $17.25M derived: sum of 2 quarters · filed 2026-05-08 | $25.15M derived: sum of 3 quarters · filed 2026-05-08 | $31.89M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $8.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $16.45M derived: sum of 2 quarters · filed 2026-02-27 | $23.20M derived: sum of 3 quarters · filed 2026-02-27 | $30.60M 10-K · filed 2026-02-27 |
| 2024-09-30 | $7.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $14.64M derived: sum of 2 quarters · filed 2025-11-06 | $22.05M 10-Q · filed 2025-11-06 | $27.92M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $6.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $14.15M 10-Q · filed 2025-08-07 | $20.02M derived: sum of 3 quarters · filed 2026-02-27 | $25.21M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $7.41M 10-Q · filed 2025-05-08 | $13.28M derived: sum of 2 quarters · filed 2026-02-27 | $18.47M derived: sum of 3 quarters · filed 2026-02-27 | $22.07M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $5.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $11.06M derived: sum of 2 quarters · filed 2026-02-27 | $14.66M derived: sum of 3 quarters · filed 2026-02-27 | $17.35M 10-K · filed 2026-02-27 |
| 2023-09-30 | $5.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $8.79M derived: sum of 2 quarters · filed 2024-11-05 | $11.48M 10-Q · filed 2024-11-05 | $13.95M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $6.29M 10-Q · filed 2024-08-06 | $8.76M derived: sum of 3 quarters · filed 2025-02-27 | $11.03M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $2.69M 10-Q · filed 2024-05-07 | $5.16M derived: sum of 2 quarters · filed 2025-02-27 | $7.43M derived: sum of 3 quarters · filed 2025-02-27 | $9.39M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.74M derived: sum of 2 quarters · filed 2025-02-27 | $6.70M derived: sum of 3 quarters · filed 2025-02-27 | $8.11M 10-K · filed 2025-02-27 |
| 2022-09-30 | $2.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.23M derived: sum of 2 quarters · filed 2023-11-09 | $5.64M 10-Q · filed 2023-11-09 | $6.93M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $3.37M 10-Q · filed 2023-08-09 | $4.67M derived: sum of 3 quarters · filed 2024-02-27 | $5.50M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $1.41M 10-Q · filed 2023-05-09 | $2.70M derived: sum of 2 quarters · filed 2024-02-27 | $3.54M derived: sum of 3 quarters · filed 2024-02-27 | $4.42M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $2.13M derived: sum of 2 quarters · filed 2024-02-27 | $3.01M derived: sum of 3 quarters · filed 2024-02-27 | $3.41M 10-K · filed 2024-02-27 |
| 2021-09-30 | $839.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.71M derived: sum of 2 quarters · filed 2022-11-09 | $2.12M 10-Q · filed 2022-11-09 | $2.45M derived: sum of 4 quarters · filed 2023-03-08 |
| 2021-06-30 | $875.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $1.28M 10-Q · filed 2022-08-10 | $1.61M derived: sum of 3 quarters · filed 2023-03-08 | $1.74M derived: sum of 4 quarters · filed 2023-03-08 |
| 2021-03-31 | $402.00K 10-Q · filed 2022-05-06 | $739.00K derived: sum of 2 quarters · filed 2023-03-08 | $864.00K derived: sum of 3 quarters · filed 2023-03-08 | $1.11M derived: sum of 4 quarters · filed 2023-03-08 |
| 2020-12-31 | $337.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $462.00K derived: sum of 2 quarters · filed 2023-03-08 | $710.00K derived: sum of 3 quarters · filed 2023-03-08 | $919.00K 10-K · filed 2023-03-08 |
| 2020-09-30 | $125.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $373.00K derived: sum of 2 quarters · filed 2021-11-04 | $582.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $248.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $457.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $209.00K 10-Q · filed 2021-05-25 | |||
| 2019-12-31 | $815.00K 10-K · filed 2022-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |